Today: 7 February 2026
Subscribe
Browse Category

LSE:GSK News 25 December 2025 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it reports full-year results next month. GSK has pencilled in Feb. 4 for its full-year and fourth-quarter update. (GSK) Big drugmakers have been under pressure to refill pipelines as a wave of patent expiries looms for the industry, helping drive a
14 January 2026
······
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

London, January 12, 2026, 08:41 GMT — Regular session Shares of GSK plc edged down 0.03% to 1,885.5 pence early Monday in London, after fluctuating between 1,870.5 and 1,885.5 pence during the session. The annual J.P. Morgan Healthcare Conference takes place January 12–15 in San Francisco. According to the agenda, GSK is scheduled for a 7:30 a.m. Pacific slot on Tuesday, followed by AstraZeneca later that morning. The San Francisco meetings this week often set the initial tone for big drugmakers each year — focusing on pipelines, pricing, and occasionally deals. Investors are on the lookout for any news that
12 January 2026
······
GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

London, Jan 11, 2026, 08:35 GMT — The market has closed. Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the 1,830 pence level, close to the 200-day moving average, as a key support zone. Why it matters now: the royalty dispute comes at a critical moment, with healthcare investors bracing for a busy news week in San Francisco and GSK’s
11 January 2026
·····
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

London, Jan 7, 2026, 07:52 GMT — Premarket GSK (GSK.L) said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24
7 January 2026
···
GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

London, January 6, 2026, 09:03 GMT — Regular session GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. sharecast.com The decision lands as investors weigh whether GSK’s next wave of respiratory launches can broaden growth beyond its established portfolio. Long-acting medicines that cut the number of injections can be a commercial lever, but they also have to win reimbursement and persuade patients and doctors to switch. The Japan approval followed a separate regulatory win in
6 January 2026
···
GSK share price today: why the stock dipped after China approved Nucala for COPD

GSK share price today: why the stock dipped after China approved Nucala for COPD

LONDON, Jan 5, 2026, 09:46 GMT — Regular session GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease (COPD). The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT.  Investing The China nod matters because it opens a new label for one of GSK’s established respiratory drugs in a market where the company estimates around 100 million people have COPD. GSK said Nucala is the first and only monthly biologic approved in China and evaluated in COPD patients with blood eosinophil counts
5 January 2026
····
London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

NEW YORK, Dec. 28, 2025, 7:52 a.m. ET — Market Closed With U.S. stock markets shut for the weekend and London also dark until Monday, investors are heading into the final stretch of 2025 with an unusually familiar year-end cocktail: thin liquidity, big cross-asset moves, and a loud debate over whether London can finally turn “capital markets reform” into actual capital markets. When the London Stock Exchange (LSE) reopens Monday, it will do so in a global backdrop where Wall Street is hovering near record territory, precious metals have been sprinting, and a growing chorus of market watchers is trying
28 December 2025
·····
London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

As of 7:53 a.m. ET in New York on Saturday, December 27, 2025, the London Stock Exchange (LSE) is closed for the weekend — and it’s also coming off the Christmas holiday break. That timing matters, because the LSE is heading into a classic “thin liquidity” stretch: fewer traders at their desks, wider bid–ask spreads, and price moves that can look louder than the underlying news. The next London session is set to reopen at 8:00 a.m. London time on Monday, December 29, according to the exchange’s own market status display. London Stock Exchange Below is the complete, up-to-date picture
27 December 2025
·····
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

December 26, 2025 — GSK plc stock is closing out the year with a familiar mix of “defensive pharma stability” and “pipeline-driven volatility.” The past two weeks delivered a cluster of headline-worthy updates: a U.S. FDA approval for GSK’s twice-yearly asthma biologic, a high-profile U.S. drug-pricing agreement that directly touches GSK’s respiratory franchise, regulatory momentum for expanded vaccine use in Europe, and fresh competitive noise around Shingrix—one of GSK’s biggest profit engines. This is a stock that rarely moves on vibes alone. For GSK shares, regulatory decisions, pricing frameworks, and evidence that new products can offset looming patent expiries are
26 December 2025
·····
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

London | Friday, 26 December 2025 — The UK stock market is effectively on pause today, with the London Stock Exchange closed for the Boxing Day bank holiday. But “no trading” doesn’t mean “no market story”: investors are spending the day digesting a strong 2025 run for the FTSE 100, fresh signals from the make-or-break retail season, and a global backdrop dominated by a year-end risk rally and a fresh spike in precious metals that could ripple through London-listed miners when UK dealing resumes. Reuters Is the UK stock market open today? No. London’s stock market is shut on Friday,
26 December 2025
·······
UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

London — 25 December 2025. UK investors heading into Friday, 26 December 2025 should start with one practical reality: there is no standard London cash equity session tomorrow. From there, attention shifts to what’s been moving the FTSE 100, the pound, commodities and rate expectations into year-end — and what could matter most when trading resumes. Is the UK stock market open on 26 December 2025? No. The London market is closed on Boxing Day (Friday, 26 December 2025). Several brokers and market schedules list 26 December as a UK market closure, with UK equities not trading in the usual
25 December 2025
····
United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

London — Thursday, 25 December 2025. The United Kingdom stock market is closed today for Christmas Day, putting a temporary pause on trading after a holiday-shortened run into the break. With the London Stock Exchange (LSE) also shut on Friday for Boxing Day, the next meaningful read on UK risk appetite will come when markets reopen after the long weekend. MoneyWeek Even with the screens dark, investors are still digesting a busy late-December backdrop: a Bank of England rate cut to 3.75%, a strong year for UK large caps, record-setting moves in industrial metals that boosted miners, and headline corporate
25 December 2025
·······
1 2 3 4 5

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop